A transthyretin variant with a methionine for valine substitution at position 30 [TTR(Met30)] is found in Portuguese patients with familial amyloidotic polyneuropathy (FAP). Effective, rapid, small-and semimicro-scale (immunoblotting) procedures were developed to determine whether or not TTR(Met30) is present in the plasma of an individual subject. The immunoblotting procedure employs only 0.10 ml of serum and can serve as a reliable procedure for the screening of large numbers of persons for the presence of TTR(Met30). In family studies of seven FAP kindreds, TTR(Met30) was found in 21 out of 41 asymptomatic FAP offspring, and its presence was not related to either age or sex. Thus, the mutant TTR segregated in accordance with the known autosomal dominant mode of inheritance of FAP. Total plasma TTR levels were not reduced in asymptomatic FAP offspring who were carriers of TTR(Met30), and no difference was observed between carriers and noncarriers of the mutant TTR. The ratios of the variant to normal TTR in plasma were estimated in asymptomatic FAP offspring and were similar to those found in FAP patients. In contrast, TTR(Met30) was relatively enriched in cerebrospinal fluid samples from two FAP patients. The significance of this finding is not known, but might relate to the preferential deposition of amyloid in the nervous system in FAP. A limited study was conducted involving simultaneous […] (Met3) is present in the plasma of an individual subject. The immunoblotting procedure employs only 0.10 ml of serum and can serve as a reliable procedure for the screening of large numbers of persons for the presence of TTR(Met3). In family studies of seven FAP kindreds, TTR(Met3') was found in 21 out of 41 asymptonatic FAP offspring, and its presence was not related to either age or sex. Thus, the mutant TTR segregated in accordance with the known autosomal dominant mode of inheritance of FAP. Total plasma TTR levels were not reduced in asymptomatic FAP offspring who were carriers of TTR(Met34), and no difference was observed between carriers and noncarriers of the mutant TTR. The ratios of the variant to normal TTR in plasma were estimated in asymptomatic FAP offspring and were similar to those found in FAP patients. In contrast, TTR(Met3') was relatively enriched in cerebrospinal fluid samples from two FAP patients. The significance of this finding is not known, but might relate to the preferential deposition of amyloid in the nervous system in FAP.
Introduction
Human plasma transthyretin (TTR)' has been related to several forms of amyloidosis and particularly to the systemic heredoPlease send correspondence and reprint requests to Dr. Goodman, Department (4, 5) , and in Japanese patients (6, 7) . TTR variants having substitutions other than the one found at position 30 have also been reported in an FAP patient of Jewish origin (8, 9) . Table I and Fig. 1 ). § n, the numbers of subjects in each group. 11 The range of ages of the subjects studied are given in parentheses. ¶ 14F, 14 Detection of TTR(Met30) by immunoblotting. In order to investigate the presence or absence ofTTR(Met30) in stored frozen samples, a sensitive immunoblotting microtechnique was developed, as described in the Methods section. Fig. 3 Fig. 3 shows that TTR(Met30) is not present in this individual.
To test further the applicability of this immunoblotting technique as a diagnostic and screening procedure, we tested all the serum samples from the seven kindreds studied above (Table  I and Fig. 1 ). For all the samples studied, the data obtained by immunoblotting agreed with the results obtained previously by I 2 -D Using the methodology described above, we conducted tryptic peptide mapping on individual TTR samples isolated from CSF. The ratio of peptide T4* to peptide T4 was concurrently estimated on TTR isolated from serum samples collected concurrently from the same patients. The ratios of TTR(Met30) to normal TTR found in the CSF samples were much higher than those found in the sera of the same individuals. Thus the ratios found for CSF were 1.4 and 1.1, whereas the corresponding ratios for the serum samples were 0.35 and 0.47, respectively. These results suggest that TTR(Met30) is present in relatively high amounts in the CSF of FAP patients. Future studies, with CSF from additional patients, will be needed to explore this issue in a definitive way. Retrospective-prospective study. Definitive proof that the presence of the variant TTR can be used as a preclinical biochemical marker of the disease will require longitudinal studies in families to determine whether offspring of patients with FAP who have the variant TTR(Met3) will always develop the clinical disease, whereas offspring without the variant TTR remain healthy. Since this kind of longitudinal prospective study will require many years offuture follow up, we have turned to frozen stored sera to try to obtain preliminary data concerning this question. In this limited retrospective-prospective study, the presence or absence of TTR(Met-) in both fresh and stored serum (collected in 1975) from the same individual was investigated by the immunoblotting technique illustrated in Fig. 3 . The samples tested were obtained both from FAP patients and from asymptomatic younger offspring of FAP patients. In addition, sera collected from a healthy 45-yr-old unaffected member of an FAP family were also analyzed.
The results obtained in this study are summarized in Table  IV . Several conclusions can be drawn from these data. First of all, in every one of the 20 subjects, the results obtained with the stored serum sample collected in 1975 agreed with those obtained with the fresh sample collected 9 yr later. Thus, either healthy subjects studied, six have TTR(Met') and eight do not.
The six positive subjects currently range in age from 20 to 25, and are hence still too young to be expected to have developed the clinical disease. These six persons require further follow-up to determine whether they will develop clinical disease as they become older.
Discussion
The major goals of the studies reported here were to determine whether the presence of the variant TTR(Met') in plasma can be used as a predictive biochemical marker of FAP in the preclinical phase ofthe disease, and to develop effective procedures for the screening of large numbers of persons for the presence of TTR(Met30). Information was also sought about the levels of TTR in plasma in FAP offspring, and about the relative levels of the variant TTR in asymptomatic carriers of the TTR(Met)30
gene.
As reported here, we have developed effective, relatively simple and rapid, small-scale and semimicro-scale (immunoblotting) procedures to determine whether or not TTR(Met30) is present in plasma (or in other biological fluids) from individual subjects. These procedures involve the demonstration ofaberrant CNBr peptides for the identification of the presence of TTR(Met30). The small-scale procedure employed TTR isolated from 10-15 ml of serum by one of two two-step procedures. The even simpler immunoblotting procedure employed only 0.10 ml of serum subjected to a single, rapid chromatographic step before digestion with CNBr. Identical results were obtained with both procedures in all the serum samples studied in the seven kindreds reported in Table I and Fig. 1 .
Recent reports have indicated that the variant TTR(Met30) circulates in plasma in some asymptomatic offspring of FAP patients of various ethnic origins (19) (20) (21) . Two kinds of studies, reported here, were conducted to explore the effectiveness and validity of using the presence of the variant TTR as a preclinical marker ofthe disease. First, family studies were carried out with both affected and nonaffected members of seven FAP kindreds (Table I and Fig. 1 [18] [19] [20] [21] [22] [23] [24] [25] will be needed to determine whether the six TTR(Met30) positive subjects develop clinical FAP as they become older, whereas the noncarriers of the mutant TTR remain healthy. With the information available, we anticipate that this will indeed be the case.
We have previously found (10) that total plasma TTR levels are significantly reduced in patients with FAP. In contrast, plasma TTR levels were not reduced in asymptomatic FAP offspring who were carriers of the variant TTR(Met30), and no difference was observed between carriers and noncarriers of the mutant TTR (Table II) . One possible explanation for these findings might be that selective deposition of the abnormal TTR(Met30) in the tissues of FAP patients leads to a reduction in plasma total TTR level. The ratios of abnormal to normal TTR observed in sera from individual asymptomatic FAP offspring (Table III) did not, however, provide support for this hypothesis. Similar, relatively low ratios of TTR(Met30) to normal TTR were found in both the asymptomatic FAP offspring and in the FAP patients. Moreover, in the FAP offspring, there was no correlation of this ratio with either age or total TTR levels.
The relative amount of TTR(Met30) has also been estimated in asymptomatic carriers of other ethnic origins (20) (21) (22) . Since a specific antibody against the intact abnormal protein is still not available, the methods used for its estimation all rely on the cleavage ofthe mixture ofthe two TTRs (normal and abnormal) in plasma, followed by the quantitative analysis ofthe abnormal fragments by either peptide mapping (as reported here), amino acid sequence analysis (20) 
